NCT02284555View on ClinicalTrials.gov

Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)

PHASE4CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions

Staphylococcal Infection

Interventions

DRUG

Mupirocin

Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.

Trial Locations (1)

CF48 4DR

Simbec Reseach Ltd, Wales

Sponsors

Lead Sponsor

Destiny Pharma Plc

All Listed Sponsors

lead

Destiny Pharma Plc

INDUSTRY